Trial

Clinical Trial Title

COG ARST08P1

Trial Status

Open to Enrollment

Start Date

March 17, 2010

Trial Type

Pediatric Cancer (Oncology)

Specific Condition

Rhabdomyosarcoma (High Risk)

Description

A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGR-IR Monoclonal Antibody, IND#100947, NSC #742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma

Eligibility Criteria

Patients must be eligible for and enrolled on D9902 prior to enrollment on ARST08P1

Age for embryonal RMS: Age > 10 years and < 50 years at the time of enrollment

Age for alveolar RMS or ectomesenchymoma: Age <50 years at the time of enrollment

Patients with newly diagnosed, biopsy proven metastatic rhabdomyosarcoma or
ectomesenchymoma (Stage IV, Clinical Group IV) are eligible for this study

No prior chemotherapy or radiation therapy except for use of corticosteroids or emergent radiation therapy

Adequate kidney, liver, heart, and hematological (blood counts) functions

Notes

Sponsor: COG Children's Oncology Group

Principal Investigator Name

Janice Olson, MD

Contact Name

Children's Cancer and Blood Disorders Program

Phone

(503) 276-9300

Last Updated: Thursday, December 13, 2012 02:03:08 PM